These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 19026268)

  • 1. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
    McGrath PJ; Khan AY; Trivedi MH; Stewart JW; Morris DW; Wisniewski SR; Miyahara S; Nierenberg AA; Fava M; Rush AJ
    J Clin Psychiatry; 2008 Dec; 69(12):1847-55. PubMed ID: 19026268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
    Bobo WV; Chen H; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Lesser IM; Kornstein SG; Wisniewski SR; Rush AJ; Shelton RC
    J Affect Disord; 2011 Oct; 133(3):467-76. PubMed ID: 21601287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.
    Rush AJ; Wisniewski SR; Warden D; Luther JF; Davis LL; Fava M; Nierenberg AA; Trivedi MH
    Arch Gen Psychiatry; 2008 Aug; 65(8):870-80. PubMed ID: 18678792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.
    Nierenberg AA; Husain MM; Trivedi MH; Fava M; Warden D; Wisniewski SR; Miyahara S; Rush AJ
    Psychol Med; 2010 Jan; 40(1):41-50. PubMed ID: 19460188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial.
    Grunebaum MF; Keilp JG; Ellis SP; Sudol K; Bauer N; Burke AK; Oquendo MA; Mann JJ
    J Clin Psychiatry; 2013 Sep; 74(9):872-9. PubMed ID: 24107760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report.
    Gilmer WS; Gollan JK; Wisniewski SR; Howland RH; Trivedi MH; Miyahara S; Fleck J; Thase ME; Alpert JE; Nierenberg AA; Warden D; Fava M; Rush AJ
    J Clin Psychiatry; 2008 Aug; 69(8):1246-56. PubMed ID: 18681756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    Trivedi MH; Rush AJ; Wisniewski SR; Nierenberg AA; Warden D; Ritz L; Norquist G; Howland RH; Lebowitz B; McGrath PJ; Shores-Wilson K; Biggs MM; Balasubramani GK; Fava M;
    Am J Psychiatry; 2006 Jan; 163(1):28-40. PubMed ID: 16390886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diurnal mood variation in outpatients with major depressive disorder.
    Morris DW; Trivedi MH; Fava M; Wisniewski SR; Balasubramani GK; Khan AY; Jain S; Rush AJ
    Depress Anxiety; 2009; 26(9):851-63. PubMed ID: 19306304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.
    Howland RH; Rush AJ; Wisniewski SR; Trivedi MH; Warden D; Fava M; Davis LL; Balasubramani GK; McGrath PJ; Berman SR
    Drug Alcohol Depend; 2009 Jan; 99(1-3):248-60. PubMed ID: 18986774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex differences in response to citalopram: a STAR*D report.
    Young EA; Kornstein SG; Marcus SM; Harvey AT; Warden D; Wisniewski SR; Balasubramani GK; Fava M; Trivedi MH; John Rush A
    J Psychiatr Res; 2009 Feb; 43(5):503-11. PubMed ID: 18752809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.
    Rush AJ; Bernstein IH; Trivedi MH; Carmody TJ; Wisniewski S; Mundt JC; Shores-Wilson K; Biggs MM; Woo A; Nierenberg AA; Fava M
    Biol Psychiatry; 2006 Mar; 59(6):493-501. PubMed ID: 16199008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.
    Perlis RH; Purcell S; Fava M; Fagerness J; Rush AJ; Trivedi MH; Smoller JW
    Arch Gen Psychiatry; 2007 Jun; 64(6):689-97. PubMed ID: 17548750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study.
    Kornstein SG; Toups M; Rush AJ; Wisniewski SR; Thase ME; Luther J; Warden D; Fava M; Trivedi MH
    J Womens Health (Larchmt); 2013 Feb; 22(2):121-31. PubMed ID: 23398127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study.
    Mrazek DA; Biernacka JM; McAlpine DE; Benitez J; Karpyak VM; Williams MD; Hall-Flavin DK; Netzel PJ; Passov V; Rohland BM; Shinozaki G; Hoberg AA; Snyder KA; Drews MS; Skime MK; Sagen JA; Schaid DJ; Weinshilboum R; Katzelnick DJ
    J Clin Psychopharmacol; 2014 Jun; 34(3):313-7. PubMed ID: 24743713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
    Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
    Trials; 2011 Jan; 12():4. PubMed ID: 21208417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
    Fava M; Rush AJ; Alpert JE; Balasubramani GK; Wisniewski SR; Carmin CN; Biggs MM; Zisook S; Leuchter A; Howland R; Warden D; Trivedi MH
    Am J Psychiatry; 2008 Mar; 165(3):342-51. PubMed ID: 18172020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do atypical features affect outcome in depressed outpatients treated with citalopram?
    Stewart JW; McGrath PJ; Fava M; Wisniewski SR; Zisook S; Cook I; Nierenberg AA; Trivedi MH; Balasubramani GK; Warden D; Lesser I; John Rush A
    Int J Neuropsychopharmacol; 2010 Feb; 13(1):15-30. PubMed ID: 19341509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melancholic features and treatment outcome to selective serotonin reuptake inhibitors in major depressive disorder: A re-analysis of the STAR*D trial.
    Szmulewicz A; Valerio MP; Lomastro J; Martino DJ
    J Affect Disord; 2024 Feb; 347():101-107. PubMed ID: 37981037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.